Abstract:Abstract Lysine methyltransferases and demethylases were identified as transcriptional co-regulators functioning by either preserving particular chromatin methylation states or by controlling placement and removal of histone lysine methylation marks to promote dynamic changes in gene expression. The development of small molecule methyltransferase and demethylase inhibitors provides a novel approach to affect the regulation of transcription, and thus potentially allowing interference with aberrant transcriptional programs as observed, for instance, in cancer. Enhancer of Zeste Homolog 2 (EZH2), the major histone H3 lysine 27 (K27) methyltransferase, is widely implicated in tumor progression. The presence of a recurrent mutation of a single tyrosine residue in the EZH2 catalytic domain in germinal center B-cell like diffuse large B-cell lymphoma (GCB-DLBCL) and follicular lymphoma suggests that these cancers might be dependent on altered EZH2 molecular function, the mutation facilitating the conversion of an H3K27 di-methylated to a tri-methylated state. Inhibition of the EZH2 catalytic activity will provide a new therapeutic approach to treat human cancers, especially lymphomas carrying activating mutations. Constellation has identified, characterized and optimized potent, selective and reversible EZH2 small molecule inhibitors as well as studied the biological impact of such inhibition. We find that pharmacological inhibition of EZH2 causes selective cell viability defects with cell lines harboring EZH2 mutations being the most sensitive. Our EZH2 inhibitors potently engage the target in vivo and exhibit efficacy in lymphoma xenograft models. Genome-wide mapping of EZH2 and H3K27me3 sites in the absence and presence of the compound revealed that the EZH2 inhibitor caused significant changes to the local chromatin modification landscape, however only a subset of these alterations translated into gene expression changes. The discovery of additional contexts that define sensitivity to EZH2 inhibitors will be discussed. Citation Format: James E. Audia, Patrick Trojer, Shivani Garapaty, Fei Lan, Vidya Balasubramanian, Eric Chan, Charles Hatton, Robert Campbell, Richard Cummings, Emmanuel Normant, Barbara Bryant, Brian Albrecht, Jean Christophe Harmange, Les Dakin, Victor Gehling, Chris Nasveschuk, Rishi Vaswani, Andrew Cook. The histone methyltransferase EZH2 catalytic activity is required for cell growth in diffuse large B-cell lymphoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4621. doi:10.1158/1538-7445.AM2013-4621

Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas

Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling

Global Characterization of Proteome and Lysine Methylome Features in EZH2 Wild-Type and Mutant Lymphoma Cell Lines.

Upregulation of Enhancer of Zeste Homolog 2 (EZH2) with Associated pERK Co-Expression and PRC2 Complex Protein SUZ12 Correlation in Adult T-Cell Leukemia/Lymphoma

Clinical Features, Tumor Biology, and Prognosis Associated with MYC Rearrangement and Myc Overexpression in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-Chop

MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive Lymphoma and Contributes to the Inferior Prognosis of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study

Abstract 4621: the Histone Methyltransferase EZH2 Catalytic Activity is Required for Cell Growth in Diffuse Large B-cell Lymphoma.

Enhancer of Zeste Homolog 2 is Overexpressed and Contributes to Epigenetic Inactivation of P21 and Phosphatase and Tensin Homolog in B-cell Acute Lymphoblastic Leukemia.

Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma

Ezh2 Promotes Malignant Behaviors Via Cell Cycle Dysregulation And Its Mrna Level Associates With Prognosis Of Patient With Non-Small Cell Lung Cancer

The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy

EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions

Higher EZH2 Expression is Associated with Extramedullary Infiltration in Acute Myeloid Leukemia.

Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomas

High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors

EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features

EZH2 is Overexpressed in Laryngeal Squamous Cell Carcinoma and Enhances the Stem-Like Properties of AMC-HN-8 Cells

EZH2 Overexpression in Primary Gastrointestinal Diffuse Large B-cell Lymphoma and Its Association with the Clinicopathological Features.

Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment.

Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.

Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.